Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2021 16:12 ET | Source: AnaptysBio, Inc.

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
April 12, 2021 16:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
March 08, 2021 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpointImsidolimab was generally well tolerated and no...
February 25, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated...
January 07, 2021 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
November 13, 2020 09:25 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
November 04, 2020 16:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates

Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 FDA end-of-Phase 2 meeting anticipated in...
October 26, 2020 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration

Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020Additional 1% royalty to AnaptysBio on GSK’s...
October 13, 2020 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29FDA...
September 11, 2020 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...